The future of precision oncology in pancreatic cancer

Benedikt Westphalen, MD, PhD, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany, discusses how precision oncology can be utilized in pancreatic cancer. Precision oncology has not been at the forefront of pancreatic cancer, as the in many classic pancreatic adenocarcinoma cases, patients have an activating mutation in KRAS. Whilst this has been previously deemed as untreatable, novel KRAS inhibitors have allowed for advancements in precision oncology. Druggable targets are present in patient with KRAS wildtype disease, but genomic profiling is recommended for targeted treatments, . Patients with germline mutations in BRCA-1 and BRCA-2 could benefit from personalized maintenance after responding to platinum-based chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.